Transforming Healthcare with Evidence

hayesinfo@hayesinc.com | 215-855-0615

We rely heavily on the currency, authority, and completeness of Hayes reviews and citations.

Steven D. Marks, MD, MHA
Chief Medical Officer & VP Health Services, PacificSource Health Plans

Coding Topics for Pharmacogenetic

Topic GTE Synopsis GTE Report
Abelson Murine Leukemia Viral Oncogene Homolog 1 (ABL1) Variant Testing in Acquired Tyrosine Kinase Inhibitor (TKI) Resistance Pending
BRAF p.Val600Glu (V600E) for Assessment of Treatment Options in Metastatic Colorectal Cancer
CYP2C19 Variant Testing for Determining Response to Clopidogrel
CYP2C9 and VKORC1 Variant Testing for Management of Warfarin Dose Initiation
CYP2D6 Genotyping for Dose Management of Tamoxifen During Breast Cancer Treatment
Cytochrome P450 3A4 (CYP3A4) for Drug Metabolism N/A *
Cytochrome P450 3A5 (CYP3A5) for Drug Metabolism N/A *
FIP1L1-PDGFRA Fusion Gene Testing for Imatinib-Sensitive Chronic Eosinophilic Leukemia/Hypereosinophilic Syndrome (CEL/HES) Pending
KIT and PDGFRA Testing for Diagnosis of GIST
KIT and PDGFRA Testing for Diagnosis of GIST
KIT and PDGFRA Testing for Primary Treatment of GIST
KIT and PDGFRA Testing for Prognosis of GIST
KIT and PDGFRA Testing for Secondary Treatment of GIST
KRAS Sequence Variant Analysis (Colorectal Cancer)
KRAS Sequence Variant Analysis (Non-small Cell Lung Cancer)
Neuroblastoma RAS Viral Oncogene (NRAS) for Prediction of Treatment Response in Colorectal Cancer Pending
TheraGuide 5-FU
Thiopurine S-Methyltransferase (TPMT) Genotyping and Phenotyping for Predicting Response to Thiopurine Drug Therapy
UGT1A1 Sequence Variant Testing


* Indicates insufficient evidence for full report.

Stay Connected!

To receive webinar announcements, email newsletters, updates, and special offers from Hayes, click here to join our mailing lists.

Social Media